The African continent is home to the world's largest un-medicated population. No wonder, then, that Big Pharma is moving to increase its presence—and profits—beyond TB medication and anti-retrovirals. If pharmaceutical companies can apply the same successful consumerist models they've deployed in the U.S. and Europe, the windfall could be enormous. Carol-Ann Gleason reports on the serious implications of Big Pharma's neoliberal push into Africa.